Phanes Therapeutics
Clinical trials sponsored by Phanes Therapeutics, explained in plain language.
-
New antibody drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called peluntamig (PT217) in people with certain neuroendocrine cancers, such as small cell lung cancer and neuroendocrine prostate cancer. The drug works by targeting two proteins (DLL3 and CD47) found on cancer cells. The trial will first find the sa…
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 23, 2026 21:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called PT886, alone or with chemotherapy or immunotherapy, in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed. The goal is to find the safest dose and see if it helps control the disease. About 258 a…
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC